Biocryst Pharmaceuticals (BCRX) Liabilities and Shareholders Equity (2010 - 2026)

Biocryst Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $465.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 3.12% year-over-year to $465.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (down 2.65% YoY), and the FY2025 full-year result was $514.2 million, up 4.84% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $465.1 million, down from $514.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $558.6 million in Q3 2022, with the low at $446.4 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $500.7 million across 5 years, with a median of $509.7 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 110.19% — and 2024, when it retreated 10.84%.
• Biocryst Pharmaceuticals' Liabilities and Shareholders Equity stood at $550.0 million in 2022, then decreased by 6.01% to $517.0 million in 2023, then fell by 5.13% to $490.4 million in 2024, then rose by 4.84% to $514.2 million in 2025, then dropped by 9.55% to $465.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $465.1 million (Q1 2026), $514.2 million (Q4 2025), and $446.4 million (Q3 2025), per Business Quant data.